US7202086B2 - Method for massive directed mutagenesis - Google Patents

Method for massive directed mutagenesis Download PDF

Info

Publication number
US7202086B2
US7202086B2 US10/362,576 US36257603A US7202086B2 US 7202086 B2 US7202086 B2 US 7202086B2 US 36257603 A US36257603 A US 36257603A US 7202086 B2 US7202086 B2 US 7202086B2
Authority
US
United States
Prior art keywords
oligonucleotides
target
pool
library
mutated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related, expires
Application number
US10/362,576
Other languages
English (en)
Other versions
US20040048268A1 (en
Inventor
Marc Delcourt
Stephane Blesa
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biomethodes SA
Original Assignee
Biomethodes SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biomethodes SA filed Critical Biomethodes SA
Assigned to BIOMETHODES reassignment BIOMETHODES ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: BLESA, STEPHANE, DELCOURT, MARC
Publication of US20040048268A1 publication Critical patent/US20040048268A1/en
Application granted granted Critical
Publication of US7202086B2 publication Critical patent/US7202086B2/en
Adjusted expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/102—Mutagenizing nucleic acids
    • C12N15/1031—Mutagenizing nucleic acids mutagenesis by gene assembly, e.g. assembly by oligonucleotide extension PCR
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/102—Mutagenizing nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1058—Directional evolution of libraries, e.g. evolution of libraries is achieved by mutagenesis and screening or selection of mixed population of organisms

Definitions

  • the present invention relates to the field of molecular biology and more particularly mutagenesis. It concerns a method for high-throughput directed mutagenesis, i.e. the formation of a great number of directed mutants within a limited time and in a limited number of stages. This method will therefore be referred to “massive mutagenesis”.
  • Mutagenesis is a technique aiming at artificially modifying the nucleotide sequence of a DNA fragment in order to modify the biological activity deriving from it. In the last decade mutagenesis has taken up an important position in numerous molecular biology studies.
  • mutagenesis can be associated with three distinct modifications of a DNA fragment:
  • Mutagenesis techniques can be classified into two main groups: random mutagenesis and directed mutagenesis.
  • random mutagenesis The purpose of random mutagenesis is to introduce substitutions of random nature and position into a DNA fragment. Random mutagenesis was formerly carried out by means of chemical processes, which alter the DNA structure. More recently, amplification of a molecule using a polymerase in particular conditions has often replaced chemical processes. These particular conditions are characterised in that they alter the capacity of the enzyme to replicate the DNA accurately. In the course of the cycles, the enzyme introduces mutations, i.e. differences from the initial sequence. At the end of the reaction, a large number of copies of the initial molecule are obtained, each of these molecules having different mutations. These molecules are present as a library, i.e. a mixture of molecules of different types (differing in the nature and position of their mutations).
  • directed mutagenesis is to introduce one or more mutations (substitutions, but also deletions or insertions) of known nature and position into a DNA fragment.
  • An oligonucleotide is used to introduce this mutation.
  • This oligonucleotide usually comprises about 20 bases.
  • the sequence of this oligonucleotide is homologous to the sequence of the target DNA fragment everywhere but in one or more positions located in its median part.
  • This oligonucleotide is then used as a primer in a replication reaction (or amplification reaction, i.e. multiple replications) using the DNA fragment as the template.
  • the newly synthesised sequence contains the desired modification.
  • the first techniques of directed mutagenesis were based on amplification of the DNA fragment of interest (only as of a fragment of linear DNA), which then had to be introduced into a plasmid. These techniques were tedious and had to be adapted to each studied system.
  • mutant oligonucleotide has been used to replicate directly the plasmid containing the DNA fragment of interest. Thus the number of operations to be carried out is reduced.
  • This low level of mutants is notably due to the fact that at the end of the directed mutagenesis reaction, the circular molecules are introduced into bacteria containing a DNA repair system which eliminates a large number of the mutations if they are carried by only one of the DNA strands.
  • the purpose of mutagenesis may be gain or loss of activity.
  • Gain of an activity is especially interesting in the field of enzymology and ligand/receptor combination.
  • providing enzymes with improved activity could make it possible to reduce the costs of industrial processes using such enzymes.
  • the affinity of the bond between a ligand and its receptor can be improved by means of a few mutations located at the recognition site.
  • Directed mutagenesis has been used in the context of a search for a gain in activity.
  • region of the active site is well known, it may be expected that directed modification of those amino acids which constitute it leads to improved activity.
  • European Patent No. 527 809 discloses sequentially replacing the amino acids in an active region with an amino acid frequently involved in active sites (for example serine) using a technique similar to directed mutagenesis.
  • this technique requires that precise information about the active site of the molecule of interest is available, and uses a technology which does not allow the introduction of a large number of modifications on a DNA fragment.
  • the present invention is an intermediate technique between directed mutagenesis and random mutagenesis. It does not aim, as it is the case in simple directed mutagenesis, at obtaining at the end of the reaction a single product containing the desired mutation or mutations, but a mixture of molecules each containing one or more of the desired mutations.
  • the present invention is a method for introducing a particular predefined type of substitution at a given position, rather than any substitution, as it is the case in random mutagenesis.
  • this method combines the advantages of directed mutagenesis (control of the nature of the modifications obtained in a given position) and of random mutagenesis (achievement of a large number of different mutations distributed over many positions in the DNA fragment to be mutated). It makes it possible to carry out a large number of directed mutations within a very short time.
  • a process of mutagenesis of a target gene which comprises preparing a pool of N oligonucleotides with a sequence substantially complementary to at least one region of the target gene, then reacting said pool of oligonucleotides with said target gene under conditions which allow production of copies of the target gene carrying at least one mutation.
  • the target gene is carried by a double-strand circular plasmid.
  • Each oligonucleotide has a sequence complementary to a different region of the target gene, with at least one mutation in the centre of the oligonucleotide sequence.
  • Said pool of oligonucleotides is then reacted with the target gene in the presence of a polymerase in order to generate a library of mutated genes where each mutation from a single oligonucleotide is present in less than 1 ⁇ 5 of the genes in the library on average.
  • the process according to the invention is remarkable in that the limitations associated with the position of the mutation and its nature are dissociated; for example, it is possible to carry out mutations of a particular type (for example any codon to alanine) throughout a coding sequence.
  • each of the mutants obtained at the end of the reaction contains one or more mutations of known nature (alanine codon) but of unknown position.
  • the process of the invention makes it possible to incorporate in some particular positions oligonucleotides containing degenerated bases. In this example, the positions are somewhat known (the number of positions is limited), but the nature of the mutations introduced is unknown.
  • Another remarkable feature of the process according to the invention consists in that the mutagenesis reaction, results in the final production of a large number of different molecules of DNA, which form a library. These molecules correspond to all the DNA molecules which have incorporated at least one mutation at predetermined sites. The number of different mutant molecules is very high because all the combinations of mutations can occur.
  • the process of mutagenesis according to the invention can also be applied to a library of mutated genes.
  • This library is then used as a template instead of the target gene.
  • a pool of N oligonucleotides with a sequence substantially complementary to at least one region of the target mutated genes is prepared and said oligdnucleotides pool is then reacted with the target mutated genes under conditions which allow the production of copies of the target mutated genes carrying at least one mutation.
  • the target mutated genes are carried by double-strand circular plasmids and each oligonucleotide has a sequence complementary to a different region of the target mutated genes with at least one mutation in the centre of the oligonucleotide sequence, and the whole of the said N oligonucleotides of the pool, with N higher than 5, encompasses part or all of the sequence of said target mutated genes.
  • Said pool of oligonucleotides is then reacted with the target mutated genes in the presence of a polymerase in order to generate a library of mutated genes where each mutation from a single oligonucleotide is present in less than 1 ⁇ 5 of the genes in the library on average.
  • the library of target mutated genes used as the template has been first obtained by massive mutagenesis.
  • the average number of mutations per molecule increases with the number of cycles of massive mutagenesis carried out.
  • N is between about 5 and 10 6 , preferably between 50 and 500, and each mutation from a single oligonucleotide is present in 1 ⁇ 5 to 1/10 6 , preferably in 1/50 to 1/500 of the genes in the library on average.
  • the process of the invention is especially directed to the case where the pool of oligonucleotides comprises N different oligonucleotides and where each mutation from a single oligonucleotide is present in about 1/N of the genes in the library on average, with N having the above value.
  • This feature distinguishes the process of the invention from the prior art, where the examples of multiple mutagenesis using several oligonucleotides simultaneously are based on levels of incorporation of each oligonucleotide of more than 75%.
  • the purpose of these approaches is to isolate the only mutants which have incorporated all the oligonucleotides, and the high levels of incorporation make it possible to achieve this easily.
  • the frequency of mutation for each of the mutations to be introduced is controlled in order to avoid the production of DNA molecules containing an excess of mutations. It is desired to get mutants each containing one mutation or a combination of some different mutations.
  • the ratio between the quantity of each mutant oligonucleotide and the quantity of template to be mutated must be controlled. This ratio is between 0.01 and 100, preferably between 0.1 and 10.
  • the reaction of the pool of oligonucleotides with the target gene or with the library of target mutated genes can be carried out using different types of polymerase, preferably heat-stable polymerases.
  • a first embodiment uses a polymerase with a strand displacement activity such as Taq polymerase, or an exonuclease 3′ ⁇ 5′ activity such as Pfu polymerase. In this embodiment the reaction can take place in the presence of a ligase.
  • a second embodiment uses a polymerase with no strand displacement or exonuclease 3′ ⁇ 5′ activity such as T4 polymerase, and in this case the reaction is carried out in the absence of a ligase.
  • the oligonucleotides in the pool have a size between 10 and 100 and preferably between 15 and 25 nucleotides. Each of them is homologous to a part of the DNA sequence to be mutated, with the exclusion of one or several positions located in its inner part, which constitute the mutation or mutations to be introduced. These oligonucleotides can be overlapping, i.e. comprise sequences common to two different adjacent regions. Preferably, all the oligonucleotides have the same orientation, so that only one strand of the target gene is replicated, which makes it possible to obtain a low level of mutagenesis.
  • the oligonucleotides are reconstructed from two oligonucleotides, according to the process described in U.S. Pat. No. 5,858,731.
  • each oligonucleotide comprises one or more mutations and preferably one to three mutations placed at the centre of its sequence.
  • Said mutations of each oligonucleotide can be chosen from among the deletions and/or insertions of one or more nucleotides.
  • a particular form of mutation comprises using degenerated oligonucleotides. This means that each oligonucleotide in the pool is present in several copies, each of these copies having a different nucleotide at the site of said mutation or mutations.
  • each mutation allows to introduce into each oligonucleotide an identical codon or a codon corresponding to the same amino acid, as substituted for the original codon of the target gene.
  • said codon corresponds to an amino acid chosen from the group Ala, Val, Gly, Leu, Ile.
  • a template is prepared, preferably a plasmid containing the DNA fragment or fragments to be mutated.
  • Different mutant oligonucleotides preferably between 5 and 10 6 and more preferably between 50 and 500, are synthesised, followed by combining all the mutant oligonucleotides. In this step, concentration of each oligonucleotide in the mixture is thus divided by the number of oligonucleotides.
  • the oligonucleotides are added to the template, i.e. to the plasmid containing the DNA fragment or fragments to be mutated, at a concentration such that the ratio between the number of template molecules and the number of molecules of each mutant oligonucleotide is between 0.01 and 100, preferably between 0.1 and 10.
  • the template is denatured by heat (about 95° C.) so that some single-strand DNA is available for a while.
  • heat about 95° C.
  • some or all of the oligonucleotides present in the mixture bind to the template at their site of homology.
  • oligonucleotides All the elements necessary to carry out replication of the template from the mutant oligonucleotides, i.e. a polymerase, a buffer allowing it to be effective, triphosphate nucleotides in sufficient amount and any necessary co-factors, are added. Then the replication reaction takes place under temperature conditions corresponding to the maximum activity of the polymerase. If appropriate, a ligase can be added during the replication stage so that the newly synthesized DNA strands bind to the 5′ end of another oligonucleotide, bound to the template at 3′ of the first oligonucleotide. In this case, the oligonucleotides are previously phosphorylated.
  • the denaturation and replication stages are optionally repeated several times.
  • the polymerase is heat-stable to avoid the need to add some more enzyme during each cycle.
  • the DNA molecules present in the mixture are of several types:
  • Some molecules which have been replicated i.e. they contain one original strand and one strand newly synthesised from one or more primers comprised by the mutant oligonucleotides.
  • the mixture obtained is subjected to digestion by the DpnI enzyme or another restriction enzyme which allows to suppress the methylated DNA molecules on the two strands and to maintain those which are not methylated or semi-methylated.
  • Competent bacteria are transformed with the above mixture and then spread on a medium containing a selective agent in order to select those bacteria which have integrated a plasmid.
  • the DNA molecules which were cleaved in the previous stage are eliminated because the presence of a complete circular plasmid is essential to survival of the bacteria in the selective medium.
  • the bacterial colonies obtained are sampled individually and used to inoculate a selective nutrient medium.
  • a plasmid DNA preparation of these cultures is then carried out in order to isolate a large amount of potentially mutant plasmid DNA. Examination of the various plasmid DNA molecules at this stage allows to calculate the mean level of incorporation of each oligonucleotide and to check that it is close to the required value.
  • the biological activity corresponding to the various batches of mutant plasmid preparations is tested.
  • the activity measured can be higher, equal or lower than that of the non-mutated fragments. If the activity is changed, the corresponding plasmid is sequenced in order to locate the mutation introduced.
  • the biological activity of the mutant molecules is tested and the result is compared with the biological activity corresponding to the non-mutated plasmid DNA molecule. If these measurements show a significant difference, the mutant molecules are sequenced in order to detect the position of the mutation which induces this change of activity. The order of these last two stages is opposite to that in conventional directed mutagenesis techniques, which generally involve obtaining and checking the mutant molecule before testing its biological activity.
  • a template is prepared consisting of a plasmid containing the target gene or the library of target mutated genes and a resistance gene
  • an equimolar pool of oligonucleotides with a sequence complementary to a different region of the target gene or the library of target mutated genes and at least one mutation at the centre of the oligonucleotide is prepared, so that the set of oligonucleotides encompasses all or part of the sequence of said target gene or genes,
  • step (b) the pool of oligonucleotides prepared in step (b) is mixed with the plasmid from step (a) in a molar ratio of each oligonucleotide to the plasmid between 0.01 and 100 and preferably between 0.1 and 10,
  • step (c) the mixture from step (c) is denatured by raising temperature to give a single-strand template
  • step (d) the mixture from step (d) is subjected to a temperature allowing hybridisation of oligonucleotides on the template,
  • steps (d), (e) and (f) are repeated,
  • step (f) or (g) which have undergone replication are selected by any appropriate means,
  • step (h) competent bacteria are transformed with the products selected in step (h) and those products with a plasmid are selected on a selective medium corresponding to the resistance gene carried by the plasmid from step (a).
  • the products from step (f) are subjected to the action of a restriction enzyme which is specific to the products which have undergone replication, such as the DpnI enzyme.
  • the oligonucleotides can be phosphorylated at their 5′ end when a ligase is added in step (f), advantageously a heat-stable ligase.
  • the mutagenesis process according to the invention is particularly useful for measuring the biological activity of the mutated proteins encoded by the mutated target genes. Consequently the target gene is a nucleic acid molecule coding for a protein of interest with or without its own regulation sequences. If the target gene does not include regulation sequences such as a promoter, the sequences are present in the plasmid.
  • the invention also relates to a process of mutagenesis of a target protein or a library of target mutated proteins, characterized by comprising preparation of an expression library of genes mutated from a target gene coding for said protein according to the mutagenesis process described above, expression of said mutated genes to produce a library of mutated proteins, and optionally screening of said mutated proteins for a desired function, advantageously in relation to the target protein.
  • the invention thus makes it possible to carry out a process of selection of mutated proteins having modified activity compared with the same non-mutated protein, or of the mutated genes corresponding to said mutated proteins, comprising the mutagenesis process as described above, screening of said mutated proteins for a desired function, advantageously in relation to the target protein, selection of the mutated protein having the desired function, and optionally sequencing of the mutated gene corresponding to said mutated protein.
  • the selective medium is incubated at an appropriate temperature for a time sufficient for growth of individual bacterial colonies
  • step (i) individual cultures of bacteria from colonies in step (i) are inoculated;
  • plasmid DNA preparations which show significant modifications of biological activity are sequenced.
  • Any further object of the invention is a pool of oligonucleotides mutated in relation to a target gene or the library of target mutated genes as defined above.
  • Still a further object of the invention is a library of mutated genes which can be obtained by the process described above, characterized in that each different mutation is present on average in less than 1 ⁇ 5 of the genes in the library and preferably on average in about 1/N of the genes in the library, where N is higher than 5, preferably between 5 and 10 6 and more preferably between 50 and 500.
  • this library is obtained, in accordance with the invention process, by using N oligonucleotides with N higher than 5, preferably between 5 and 10 6 and more preferably between 50 and 500.
  • FIG. 1 represents a distribution of the mutant oligonucleotides on the sequence of the CD4 molecule.
  • Each of the oligonucleotides contains 3 mutations at most, represented by the break of the arrow line, located in its centre, intended to change said codon into alanine.
  • the oligonucleotides overlap each other and are represented on 3 levels for sake of clarity. In the example in FIG. 1 , only 24 mutant oligonucleotides are represented. In example 1 below, 95 oligonucleotides were used simultaneously. In this example all the oligonucleotides carrying the mutations have the same orientation.
  • FIG. 2 is a diagram showing the steps of the mutagenesis process according to the invention from the mutant oligonucleotides in FIG. 1 .
  • the mutations in the DNA molecules are represented by a vertical line.
  • the letters mean:
  • FIG. 3 shows an example of construction of mutant oligonucleotides from semi-oligonucleotides comprising ligation by T4 ligase.
  • FIG. 4 gives examples of schematic representation of oligonucleotides containing bases degenerated at the points of mutation.
  • the letter N means that any of the four bases can be present in this position.
  • the contemplated oligonucleotide thus comprises a mixture of 4 N molecular species.
  • SEQ ID NO:1 relates to the described 4 molecular species
  • SEQ ID NO:2 relates to the described 16 molecular species
  • SEQ ID NO:3 relates to the described 64 molecular species.
  • a gene coding for the molecule CD4 was introduced into the vector SK+.
  • the first 95 codons of this gene were the target of a massive mutagenesis reaction according to the invention process.
  • a pool of 95 oligonucleotides of 21 bases were synthesized. Each of these oligonucleotides was complementary to a sequence of the CD4 gene centred on a codon.
  • the first oligonucleotide was homologous to a sequence centred at codon 1. It was homologous to the sequence of 9 bases on each side of said codon, but it contained 3 mutations, in order to convert the first codon into an alanine codon ( FIG. 1 ).
  • the second oligonucleotide was centred at the second codon and contained 3 adjacent mutations in its middle.
  • the 95 oligonucleotides which overlapped each other and were all in the same orientation, were then mixed in equimolar amount and phosphorylated using the T4 kinase in standard conditions.
  • SK-CD4 template 250 ⁇ g/ ⁇ l: 1 ⁇ l MIX of the 95 nucleotides 5′P (0.5 ⁇ M each) 2 ⁇ l dNTP triphosphates (2.5 mM) 10 ⁇ l 10X of Pfu polymerase buffer 2.5 ⁇ l ATP 10 mM 0.5 ⁇ l Pfu polymerase (2.5 U/ ⁇ l) 1 ⁇ l Pfu ligase (4 U/ ⁇ l) 1 ⁇ l H 2 O 7 ⁇ l Total 25 ⁇ l
  • the mixture was subjected to reaction during 12 temperature cycles [(94° C., 1′); (35° C., 1′); 68° C., 20′)].
  • the reaction mixture was then subjected to digestion by 5 units of DpnI enzyme in appropriate buffer, for 30 minutes at 37° C.
  • Competent bacteria were converted by this mixture using a thermal shock protocol and spread on a Petri dish containing the appropriate selective agent.
  • FIG. 2 A schematic diagram of the steps of the technique is given in FIG. 2 .
  • mutant molecules were then amplified by bacterial culture and plasmid DNA preparation.
  • Each of the plasmid DNA batches corresponding to a single type of mutant molecule was used to transfect eucaryote cells, and these cells were tested for conservation or loss of the epitopes carried by the CD4 molecule, whereby this activity was measured by anti-CD4 antibody binding.
  • a pool of 11 oligonucleotides were each reconstructed from two double-strand semi-oligonucleotides.
  • the two semi-oligonucleotides were ligated by reaction with T4 ligase. Since only one of the two semi-oligonucleotides was phosphorylated at one of its 5′ ends, this reaction resulted in forming a single complete oligonucleotide, comprising 18 bases (8 on each side were homologous, while the two median always were GT ( FIG. 3 ).
  • valine codons can be written as GTN, where N is any of the 4 bases.
  • a mean incorporation frequency of the mutant oligonucleotides of about 9% ( 1/11) was sought in this example.
  • amino acids included in the active site of a protein After the amino acids included in the active site of a protein have been determined, for example from massive mutagenesis data as shown in the previous examples, these amino acids can be subjected to saturation massive mutagenesis, i.e. introducing a large number of different codons to replace a particular codon. Thus 6 codons of the gene coding for the agaB protein, an enzyme involved in the synthesis of sugars, were identified as directly involved in this enzyme activity.
  • a mean incorporation frequency of the mutant oligonucleotides of about 17% (1 ⁇ 6) was sought in this example.
  • this example shows the adaptability of the technique according to the invention to random mutagenesis (change of a codon into a large number of other codons) in pre-determined positions.
  • Genes generally contain codons which do not favour the expression of the proteins which they encode. These unfavourable codons can be seen as a mechanism for regulation of the gene expression. These unfavourable codons are rather well identified and it may be necessary to modify them into a codon more favourable to the expression of the protein without changing any amino acid.
  • a library of mutations covering these unfavourable codons can be prepared using the technique of the invention, and the mutant molecules presenting the best expression levels are then selected.
  • a mutant oligonucleotide For each unfavourable codon, a mutant oligonucleotide must be synthesized with the mutations carried by these oligonucleotides being such that they change an unfavourable codon into a favourable codon, without changing the primary sequence of the corresponding protein.
  • the mean incorporation frequency of the mutant oligonucleotides can be sought in a relatively wide range, for example between 1 and 20%.
  • the number of simultaneous mutations which allows to obtain the best expression levels, is not known.
  • several libraries corresponding to different incorporation frequencies can be prepared. In order to prepare these libraries with different mutation levels, either the described process can be carried out using variable concentrations of oligonucleotides or the massive mutagenesis process can be carried out several times, i.e. using the library of mutants produced in a first massive mutagenesis as the template for a second massive mutagenesis.
  • the process is similar to what is presented in example 1.
  • the mutant molecules are then screened depending on their expression level, i.e. the molecules with the best expression levels are selected.
US10/362,576 2000-08-25 2001-08-24 Method for massive directed mutagenesis Expired - Fee Related US7202086B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR00/10962 2000-08-25
FR0010962A FR2813314B1 (fr) 2000-08-25 2000-08-25 Procede de mutagenese dirigee massive
PCT/FR2001/002666 WO2002016606A2 (fr) 2000-08-25 2001-08-24 Procede de mutagenese dirigee massive

Publications (2)

Publication Number Publication Date
US20040048268A1 US20040048268A1 (en) 2004-03-11
US7202086B2 true US7202086B2 (en) 2007-04-10

Family

ID=8853747

Family Applications (1)

Application Number Title Priority Date Filing Date
US10/362,576 Expired - Fee Related US7202086B2 (en) 2000-08-25 2001-08-24 Method for massive directed mutagenesis

Country Status (11)

Country Link
US (1) US7202086B2 (fr)
EP (1) EP1311670B1 (fr)
JP (1) JP5068917B2 (fr)
AT (1) ATE354653T1 (fr)
AU (1) AU2001286009A1 (fr)
CA (1) CA2420721C (fr)
DE (1) DE60126786T2 (fr)
DK (1) DK1311670T3 (fr)
ES (1) ES2282285T3 (fr)
FR (1) FR2813314B1 (fr)
WO (1) WO2002016606A2 (fr)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009018449A1 (fr) * 2007-07-31 2009-02-05 Verenium Corporation Assemblage combinatoire multi-sites sur mesure
USRE45349E1 (en) 1999-06-14 2015-01-20 Bp Corporation North America Inc. Synthetic ligation reassembly in directed evolution
WO2015011285A2 (fr) 2013-07-26 2015-01-29 Biomethodes Nouveaux variants d'endoglucanases de trichoderma reesei
US9903873B2 (en) 2005-06-10 2018-02-27 Biomethodes Method for selecting stable proteins in non-standard physicochemical conditions

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6958213B2 (en) 2000-12-12 2005-10-25 Alligator Bioscience Ab Method for in vitro molecular evolution of protein function
US20020086292A1 (en) 2000-12-22 2002-07-04 Shigeaki Harayama Synthesis of hybrid polynucleotide molecules using single-stranded polynucleotide molecules
US20040142433A1 (en) * 2001-02-02 2004-07-22 Padgett Hal S. Polynucleotide sequence variants
DE60234159D1 (de) * 2001-02-02 2009-12-10 Large Scale Biology Corp Methode zur erhöhung der komplementarität in einem heteroduplex-polynucleotid
US20050153283A1 (en) * 2002-08-08 2005-07-14 Padgett Hal S. Method of increasing complementarity in a heteroduplex
US7838219B2 (en) * 2001-02-02 2010-11-23 Novici Biotech Llc Method of increasing complementarity in a heteroduplex
US7582423B2 (en) 2001-02-02 2009-09-01 Novici Biotech Llc Population of polynucleotide sequence variants
FR2823219B1 (fr) * 2001-04-10 2003-07-04 Pasteur Institut Mutants de la desoxycytidine kinase possedant une activite enzymatique elargie
US7647184B2 (en) 2001-08-27 2010-01-12 Hanall Pharmaceuticals, Co. Ltd High throughput directed evolution by rational mutagenesis
US7078211B2 (en) * 2002-02-01 2006-07-18 Large Scale Biology Corporation Nucleic acid molecules encoding endonucleases and methods of use thereof
CA2498319A1 (fr) 2002-09-09 2004-03-18 Nautilus Biotech Evolution rationnelle de cytokines pour une plus grande stabilite, les cytokines et molecules d'acide nucleique codant
DE602004020570D1 (de) * 2003-12-18 2009-05-28 Biomethodes Verfahren zur ortspezifischen Massenmutagenese
FR2883885B1 (fr) * 2005-04-05 2010-12-10 Biomethodes Recombinaison in vitro circulaire
GB2432366B (en) * 2005-11-19 2007-11-21 Alligator Bioscience Ab A method for in vitro molecular evolution of protein function
FR2897068B1 (fr) * 2006-02-03 2008-04-18 Biomethodes Sa Kanamycine kinase ii amelioree et utilisations de celle-ci
WO2007101949A2 (fr) * 2006-03-08 2007-09-13 Biomethodes Variants de l'interferon- gamma humain (infgamma)
EP2931749B1 (fr) 2012-12-17 2019-04-24 Laboratoire Francais du Fractionnement et des Biotechnologies Societe Anonyme Utilisation d'anticorps monoclonaux pour le traitement de l'inflammation et d'infections bacteriennes
WO2019126211A1 (fr) * 2017-12-20 2019-06-27 Basf Se Procédé de mutagénèse de saturation de site génique (gssm)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4960707A (en) * 1987-08-17 1990-10-02 Associated Universities, Inc. Recombinant plasmids for encoding restriction enzymes DpnI and DpnII of streptococcus pneumontae
US5605793A (en) * 1994-02-17 1997-02-25 Affymax Technologies N.V. Methods for in vitro recombination
US5798208A (en) 1990-04-05 1998-08-25 Roberto Crea Walk-through mutagenesis
US5830696A (en) * 1996-12-05 1998-11-03 Diversa Corporation Directed evolution of thermophilic enzymes
US6368861B1 (en) * 1999-01-19 2002-04-09 Maxygen, Inc. Oligonucleotide mediated nucleic acid recombination

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993020096A1 (fr) * 1991-05-08 1993-10-14 Stratagene Bibliotheques d'oligonucleotides utiles pour la production d'amorces
US6620597B1 (en) * 1998-01-09 2003-09-16 University Of Utah Research Foundation Method for in vitro amplification of circular DNA

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4960707A (en) * 1987-08-17 1990-10-02 Associated Universities, Inc. Recombinant plasmids for encoding restriction enzymes DpnI and DpnII of streptococcus pneumontae
US5798208A (en) 1990-04-05 1998-08-25 Roberto Crea Walk-through mutagenesis
US5605793A (en) * 1994-02-17 1997-02-25 Affymax Technologies N.V. Methods for in vitro recombination
US5811238A (en) * 1994-02-17 1998-09-22 Affymax Technologies N.V. Methods for generating polynucleotides having desired characteristics by iterative selection and recombination
US5830696A (en) * 1996-12-05 1998-11-03 Diversa Corporation Directed evolution of thermophilic enzymes
US6368861B1 (en) * 1999-01-19 2002-04-09 Maxygen, Inc. Oligonucleotide mediated nucleic acid recombination

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
Grundstrom et al. "Oligonucieotide-directed mutagenesis by microscale 'shot-gun' gene synthesis" Nuclic Acids Research 13: 3305-3316 (1985). *
New England Biolabs Catalog, p. 70 (1995). *
Perlak, F.J. Single step large scale site-directed in vitro mutagenesis using multiple oligonucleotides. Nucleic Acids Research 18(24) : 7457-7458 (1990). *
Picard et al. A rapid and efficient one-tube PCR-based mutagenesis technique using Pfu DNA polymerase. Nucleic Acids Resaearch 22(13) : 2587-2591 (1994). *
Stemmer, W.P. Rapid Evolution of a protein in vitro by DNA shuffling. Nature 370 : 389-391 (Aug. 1994). *
Wells et al. "Cassette mutagenesis: an efficient method for generation of multiple mutations at defined sites" Gene 34 : 315-323(1985). *
Xiao et al Science in China, Series C: Life Sciences, vol. 40, No. 4, 1997, pp. 337-344, XP000993443 "Construction and screening of a multi-point site-specific mutant library of subtilisin E with a set of oligonucleotides".

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE45349E1 (en) 1999-06-14 2015-01-20 Bp Corporation North America Inc. Synthetic ligation reassembly in directed evolution
US9903873B2 (en) 2005-06-10 2018-02-27 Biomethodes Method for selecting stable proteins in non-standard physicochemical conditions
WO2009018449A1 (fr) * 2007-07-31 2009-02-05 Verenium Corporation Assemblage combinatoire multi-sites sur mesure
KR20100045494A (ko) * 2007-07-31 2010-05-03 베레늄 코포레이션 맞춤형 멀티사이트 조합 어셈블리
US20100216192A1 (en) * 2007-07-31 2010-08-26 Xuqiu Tan Tailored multi-site combinatorial assembly
CN101821402A (zh) * 2007-07-31 2010-09-01 维莱尼姆公司 修剪式多位点组合装配
CN101821402B (zh) * 2007-07-31 2015-03-04 Bp法人北美有限公司 修剪式多位点组合装配
EP3031919A1 (fr) 2007-07-31 2016-06-15 BP Corporation North America Inc. Assemblage combinatoire multi-sites sur mesure
US9476078B2 (en) 2007-07-31 2016-10-25 Basf Enzymes Llc Tailored multi-site combinatorial assembly
WO2015011285A2 (fr) 2013-07-26 2015-01-29 Biomethodes Nouveaux variants d'endoglucanases de trichoderma reesei

Also Published As

Publication number Publication date
WO2002016606A3 (fr) 2002-06-27
EP1311670B1 (fr) 2007-02-21
ATE354653T1 (de) 2007-03-15
DK1311670T3 (da) 2007-06-18
DE60126786D1 (de) 2007-04-05
US20040048268A1 (en) 2004-03-11
WO2002016606A2 (fr) 2002-02-28
FR2813314A1 (fr) 2002-03-01
CA2420721C (fr) 2013-11-12
JP5068917B2 (ja) 2012-11-07
AU2001286009A1 (en) 2002-03-04
JP2004507243A (ja) 2004-03-11
FR2813314B1 (fr) 2004-05-07
EP1311670A2 (fr) 2003-05-21
DE60126786T2 (de) 2007-11-08
ES2282285T3 (es) 2007-10-16
CA2420721A1 (fr) 2002-02-28

Similar Documents

Publication Publication Date Title
US7202086B2 (en) Method for massive directed mutagenesis
US5976846A (en) Method for multifragment in vivo cloning and mutation mapping
Wertman et al. Systematic mutational analysis of the yeast ACT1 gene.
US7199233B1 (en) Artificial promoter libraries for selected organisms and promoters derived from such libraries
US7402383B2 (en) Process for preparing variant polynucleotides
CN112795551B (zh) 一种耐高温逆转录酶突变体及其应用
EA020657B1 (ru) Специализированная многосайтовая комбинаторная сборка
EP1409666B1 (fr) Procede de preparation de polynucleotides variants
CN1399684A (zh) 使用转座和重组以操作和测序核酸分子的方法
CN112795546A (zh) 一种具有高逆转录效率的耐高温逆转录酶突变体及其应用
US6232112B1 (en) Reagents and methods for diversification of DNA
CN112795547A (zh) 高逆转录效率的逆转录酶突变体
CN112795548A (zh) 具有高逆转录效率的耐高温逆转录酶突变体及其应用
CN112795550A (zh) 耐高温逆转录酶突变体
CN114480337B (zh) 逆转录酶突变体及逆转录方法
CN114480329B (zh) 高效率mmlv酶突变体
CN111575251B (zh) 一种用于达托霉素生物合成的dptC1突变体的构建
US20050153343A1 (en) Method of massive directed mutagenesis
CN112795549B (zh) 一种逆转录酶突变体
JP4479199B2 (ja) 挿入ｄｎａユニットを含むプラスミドの製造方法
CN114480334A (zh) 用于新冠病毒检测的逆转录酶突变体
US20020160380A1 (en) Combinatorial libraries by recombination in yeast and analysis method
CN114480338B (zh) 用于核酸检测的逆转录酶突变体
CN114480333B (zh) 逆转录酶突变体及其应用
CN114480332B (zh) 耐高温m-mlv酶突变体及其应用

Legal Events

Date Code Title Description
AS Assignment

Owner name: BIOMETHODES, FRANCE

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:DELCOURT, MARC;BLESA, STEPHANE;REEL/FRAME:014413/0385

Effective date: 20030325

STCF Information on status: patent grant

Free format text: PATENTED CASE

FPAY Fee payment

Year of fee payment: 4

FPAY Fee payment

Year of fee payment: 8

FEPP Fee payment procedure

Free format text: MAINTENANCE FEE REMINDER MAILED (ORIGINAL EVENT CODE: REM.); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

LAPS Lapse for failure to pay maintenance fees

Free format text: PATENT EXPIRED FOR FAILURE TO PAY MAINTENANCE FEES (ORIGINAL EVENT CODE: EXP.); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

STCH Information on status: patent discontinuation

Free format text: PATENT EXPIRED DUE TO NONPAYMENT OF MAINTENANCE FEES UNDER 37 CFR 1.362

FP Lapsed due to failure to pay maintenance fee

Effective date: 20190410